Adjuvant (Alliance A011801 Compass HER2 Residual Disease)
- Result Type
- clinical trial
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Get personalized, coordinated care across Northern California through the Sutter network.
View Patient ResourcesMake appointments, message your doctor and more through our patient portal.
Enroll NowAccess award-winning, comprehensive primary and specialty care for your whole family.
View All ServicesOur contributions to medical research and education lead to better healthcare outcomes.
Research at SutterJoin our robust training programs led by nationally known healthcare leaders.
Explore OpportunitiesExplore the ways we provide innovative, compassionate care through our network.
Learn About Sutter HealthShape the future of healthcare and build your career within our diverse teams.
Find JobsGet personalized, coordinated care across Northern California through the Sutter network.
View Patient ResourcesMake appointments, message your doctor and more through our patient portal.
Enroll NowMake appointments, message your doctor and more through our patient portal.
Enroll NowAccess award-winning, comprehensive primary and specialty care for your whole family.
View All ServicesOur contributions to medical research and education lead to better healthcare outcomes.
Research at SutterJoin our robust training programs led by nationally known healthcare leaders.
Explore OpportunitiesJoin our robust training programs led by nationally known healthcare leaders.
Explore OpportunitiesExplore the ways we provide innovative, compassionate care through our network.
Learn About Sutter HealthShape the future of healthcare and build your career within our diverse teams.
Find JobsShape the future of healthcare and build your career within our diverse teams.
Find JobsYou are viewing results from Research and Clinical Trials.
12results found for:
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Status: Active, Not Recruiting
Evaluating the Addition of Adj Chemo to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients
Status: Active, Recruiting
The purpose of this study is to find out how genetics, biologics and behavior might contribute to
Status: Active, Recruiting
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Status: Active, Recruiting
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
Status: Active, Recruiting
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Status: Active, Recruiting
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Status: Active, Recruiting
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice o
Status: Active, Recruiting
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Particip
Status: Active, Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast
Status: Active, Recruiting
Check-ups, screenings and sick visits for adults and children.
Expertise and advanced technologies in all areas of medicine.
For serious accidents, injuries and conditions that require immediate medical care.
After-hours, weekend and holiday services.
Convenient walk-in care clinics for your non-urgent health needs.